FDA denies approval for Actavis hypertension treatment

By

Generic drug maker Actavis Plc said the U.S. health regulator denied an approval for its hypertension treatment, a fixed-dose combination of nebivolol and valsartan.

The company said it would review the U.S. Food and Drug Administration's complete response letter and decide on appropriate next steps.

The regulator issues a complete response letter when a new or generic treatment cannot be approved in its current form.

Actavis did not give any further details on the contents of the letter.

In a study, the drug combination was found more effective in reducing blood pressure in patients of hypertension, compared with independent doses of nebivolol and valsartan, Actavis said.

The company's shares closed at $254.20 on the New York Stock Exchange on Wednesday.

Tags
U.S., U.S. Food and Drug Administration
Join the Discussion
More News
Elizabeth Ferguson

Texas Woman Viciously Bludgeoned in Random Lunchtime Attack Breaks Silence: 'Those Entire Two Days are Completely Gone'

Elon Musk

Election Officials Call Elon Musk a 'Huge Problem' For His Role in Spreading Misinformation Ahead of Election Day

Man Fed Up with Sister Cleaning His Room Gets Court

Man Fed Up with Sister Cleaning His Room Gets Court to Make Her Stop

Candace Craig and Salia Hardy

Maryland Woman Reveals Mom's Sick Plot to Dispose of Dismembered Grandma's Body Using Chainsaw and A Grill

Real Time Analytics